Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 451912, 11 pages
http://dx.doi.org/10.1155/2015/451912
Research Article

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment

1Department of Medicine, Division of Neurology and Brain Research Centre, UBC Hospital, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
2Department of Statistics, University of British Columbia, 3182 Earth Sciences Building, 2207 Main Mall, Vancouver, BC, Canada V6T 1Z4
3College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, SK, Canada S7N 5C9
4Department of Public Health Sciences, Karolinska Institutet, 171 77 Stockholm, Sweden

Received 5 September 2014; Revised 28 February 2015; Accepted 2 March 2015

Academic Editor: Eberval G. Figueiredo

Copyright © 2015 Afsaneh Shirani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 359, no. 9313, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Kingwell, M. van der Kop, Y. Zhao et al., “Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 83, no. 1, pp. 61–66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Marrie, N. Yu, J. Blanchard, S. Leung, and L. Elliott, “The rising prevalence and changing age distribution of multiple sclerosis in Manitoba,” Neurology, vol. 74, no. 6, pp. 465–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Arias, D. Dapena, S. Arias-Rivas et al., “Late onset multiple sclerosis,” Neurologia, vol. 26, no. 5, pp. 291–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Etemadifar, S.-H. Abtahi, A. Minagar, M. Akbari, A. Masaeli, and N. Tabrizi, “Lateonset multiple sclerosis in Isfahan, Iran,” Archives of Iranian Medicine, vol. 15, no. 10, pp. 596–598, 2012. View at Google Scholar · View at Scopus
  6. B. Kis, B. Rumberg, and P. Berlit, “Clinical characteristics of patients with late-onset multiple sclerosis,” Journal of Neurology, vol. 255, no. 5, pp. 697–702, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Lyon-Caen, G. Izquierdo, R. Marteau, F. Lhermitte, P. Castaigne, and J. J. Hauw, “Late onset multiple sclerosis. A clinical study of 16 pathologically proven cases,” Acta Neurologica Scandinavica, vol. 72, no. 1, pp. 56–60, 1985. View at Google Scholar · View at Scopus
  8. V. Martinelli, M. Rodegher, L. Moiola, and G. Comi, “Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis,” Neurological Sciences, vol. 25, supplement 4, pp. S350–S355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Noseworthy, D. Paty, T. Wonnacott, T. Feasby, and G. Ebers, “Multiple sclerosis after age 50,” Neurology, vol. 33, no. 12, pp. 1537–1544, 1983. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Tremlett and V. Devonshire, “Is late-onset multiple sclerosis associated with a worse outcome?” Neurology, vol. 67, no. 6, pp. 954–959, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Polliack, Y. Barak, and A. Achiron, “Late-onset multiple sclerosis,” Journal of the American Geriatrics Society, vol. 49, no. 2, pp. 168–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Qiu, J.-S. Wu, A. Castley et al., “Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia,” Journal of Clinical Neuroscience, vol. 17, no. 8, pp. 1009–1013, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Poser, D. W. Paty, and L. Scheinberg, “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Annals of Neurology, vol. 13, no. 3, pp. 227–231, 1983. View at Publisher · View at Google Scholar · View at Scopus
  14. The IFNB Multiple Sclerosis Study Group, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, no. 4, pp. 655–661, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. “Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group,” The Lancet, vol. 352, pp. 1498–1504, 1998.
  16. L. D. Jacobs, D. L. Cookfair, R. A. Rudick et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG),” Annals of Neurology, vol. 39, pp. 285–294, 1996. View at Google Scholar
  17. A. D. Sadovnick, G. C. Ebers, R. W. Wilson, and D. W. Paty, “Life expectancy in patients attending multiple sclerosis clinics,” Neurology, vol. 42, no. 5, pp. 991–994, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. V. P. Sweeney, A. D. Sadovnick, and V. Brandejs, “Prevalence of multiple sclerosis in British Columbia,” Canadian Journal of Neurological Sciences, vol. 13, no. 1, pp. 47–51, 1986. View at Google Scholar · View at Scopus
  19. A. Shirani, Y. Zhao, M. E. Karim et al., “Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis,” Journal of the American Medical Association, vol. 308, no. 3, pp. 247–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, and Y. Zhao, “Impact of multiple sclerosis relapses on progression diminishes with time,” Neurology, vol. 73, no. 20, pp. 1616–1623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Tremlett, D. Paty, and V. Devonshire, “Disability progression in multiple sclerosis is slower than previously reported,” Neurology, vol. 66, no. 2, pp. 172–177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. F. D. Lublin, S. C. Reingold, and National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology, vol. 46, no. 4, pp. 907–911, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Publisher · View at Google Scholar · View at Scopus
  25. BC Ministry of Health, Data Extract, PharmaNet. BC Ministry of Health, Data Stewardship Committee, 2010, http://www.popdata.bc.ca/data.
  26. British Columbia Ministry of Health, Discharge Abstract Database (Hospital Separations), Data Extract, MOH, Population Data BC, 2010, http://www.popdata.bc.ca/data.
  27. British Columbia Ministry of Health [creator], Medical Services Plan (MSP) Payment Information File, Population Data BC, 2010, http://www.popdata.bc.ca/data.
  28. British Columbia Ministry of Health, Consolidation File (MSP Registration & Premium Billing), Population Data BC, Data Extract. MOH, 2009, http://www.popdata.bc.ca/data.
  29. Multiple Sclerosis Society of Canada, “Treatments—modifying the disease course,” http://mssociety.ca/en/treatments/modify.htm.
  30. S. Suissa, “Immortal time bias in observational studies of drug effects,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 3, pp. 241–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Phadke, “Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis,” Brain, vol. 113, no. 6, pp. 1597–1628, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Awad and O. Sütve, “Multiple sclerosis in the elderly patient,” Drugs and Aging, vol. 27, no. 4, pp. 283–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Kappos, J. Antel, G. Comi et al., “Oral fingolimod (FTY720) for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 355, no. 11, pp. 1124–1140, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. D. H. Miller, O. A. Khan, W. A. Sheremata et al., “A controlled trial of natalizumab for relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 348, no. 1, pp. 15–23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Panitch, A. Miller, D. Paty, and B. Weinshenker, “Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study,” Neurology, vol. 63, no. 10, pp. 1788–1795, 2004. View at Google Scholar · View at Scopus
  36. A. Shirani, Y. Zhao, E. Kingwell, P. Rieckmann, and H. Tremlett, “Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009),” Multiple Sclerosis, vol. 18, no. 4, pp. 442–450, 2012. View at Publisher · View at Google Scholar · View at Scopus